Comparison of Local Methylcobalamin and Subcutaneous Lidocaine in Subacute Herpetic Neuralgia

November 9, 2026 updated by: Hijab Fatima, CMH Multan Institute of Medical Sciences

Comparison of Local Methylcobalamin Injection Versus Subcutaneous Lidocaine Injection in Patients With Subacute Herpetic Neuralgia

This randomized controlled trial will compare methylcobalamin and lidocaine injections for pain relief in 60 patients with subacute herpetic neuralgia over four weeks.

Study Overview

Status

Recruiting

Detailed Description

This randomized controlled trial will compare the efficacy of local subcutaneous methylcobalamin injection versus subcutaneous lidocaine injection in patients aged 40-70 years with unilateral subacute herpetic neuralgia and baseline pain score greater than 6 on the visual analogue scale (VAS). A total of 60 patients will be randomly allocated to two groups, with 30 patients in each group. Group A will receive methylcobalamin injection (1 mg/2 mL), while Group B will receive lidocaine injection (1%, 2 mL), six times per week for four weeks. Pain intensity and sleep disturbance will be assessed at baseline and after 28 days of treatment. Treatment efficacy will be defined as a pain score below 3 at the end of treatment. Adverse effects will also be monitored and recorded. The study will be conducted at the Department of Dermatology, Combined Military Hospital (CMH), Multan, over six months following synopsis approval.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab Province
      • Multan, Punjab Province, Pakistan, 60000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

>Inclusion Criteria:

  • Patients aged 40-70 years, male or female.
  • Unilateral subacute herpetic neuralgia, defined as dermatomal neuropathic pain more than 30 days and up to 90 days after rash onset.
  • Baseline pain score greater than 6 on the Visual Analogue Scale (VAS).

Exclusion Criteria:

  • Diffuse neuropathic pain extending beyond the affected dermatome.
  • Cognitive impairment.
  • Use of topical agents or nerve-blocking agents within 10 days before enrolment.
  • Immunocompromised patients receiving steroids at a dose of 2 mg/kg/day for more than 14 days or undergoing chemotherapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Methylcobalamin Injection Group

Participants will receive local subcutaneous methylcobalamin injection (1 mg/2 mL), six times per week for four weeks.

Methylcobalamin injection (1 mg/2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.

Active Comparator: Lidocaine Injection Group

Participants will receive local subcutaneous lidocaine injection (1%, 2 mL), administered six times per week for four weeks.

Lidocaine inLidocaine injection (1%, 2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain score
Time Frame: Baseline (Day 1) and Day 28 (end of treatment).

Change in pain intensity measured using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (maximum bearable pain). Treatment efficacy is defined as a pain score below 3 at 28 days after randomization.

Baseline (Day 1) and Day 28 (end of treatment).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep Disturbance Score
Time Frame: Baseline (Day 1) and Day 28 (end of treatment).

Sleep disturbance assessed using a numeric rating scale ranging from 0 (no disturbance) to 10 (severe disturbance).

Baseline (Day 1) and Day 28 (end of treatment).
Adverse Effects
Time Frame: Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.

Assessment and recording of adverse effects, including redness, swelling, hematoma formation, dizziness, and urticaria following injections.

Throughout the 4-week treatment period (Days 1-28). with observation for one hour after each injection session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

October 28, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • File no 13/Trg--ERC No 132/26

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe